meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 2nd line (L2)
1
myofibroblastic tumors
neurofibroma
neutropenia
new pathology
osteosarcoma
ovarian cancer (OC)
9
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus pomalidomide and dexamethasone
versus all
vs Immunosuppressant
vs pomalidomide based treatment
vs pomalidomide and dexamethasone
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
SAE (any grade)
Hepatitis TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Stevens-Johnson syndrome TRAE (grade 3-4)
Anaemia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dizziness AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Headache AE (grade 3-4)
Increased ALT AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Pneumonia AE (grade 3-4)
Pyrexia AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
DCR
multiple myeloma - 2nd line (L2)
multiple myeloma - 2nd line (L2)
versus pomalidomide and dexamethasone
pembrolizumab plus pomalidomide and dexamethasone vs. pomalidomide and dexamethasone
1
certainty unassessable
+1%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open